Reversal of Doxorubicin Resistance in Human Breast Adenocarcinoma (MCF-7) Cells by Liposomal Monensin

2002 ◽  
Author(s):  
Mandip S. Sachdeva ◽  
Krishna Agrawal
2021 ◽  
Vol 7 (7) ◽  
pp. 67004-67014
Author(s):  
Camila Franco ◽  
Manoela Lunkes Silva ◽  
Altevir Rossato Viana ◽  
Aline Ferreira Ourique ◽  
Luciana Maria Fontanari Krause

Novas pesquisas indicam que anti-inflamatórios podem ser aplicados como agentes anti-cancerígenos como indometacina para hepatocarcinoma humano, canceres de colon e estômago. Como sabe-se, indometacina possui efeitos adversos gastrointestinais, cardiovasculares e renais. Uma vez que cancer de mama tem alta incidência e não há estudo da indometacina carreada em nanopartículas para esta aplicação, este estudo envolve o desenvolvimento de nanocapsulas de poli-epsilon-caprolactona carregadas com indometacina para a redução de citotoxicidade como agente quimioprotetor para cancer de mama. O nanocarreador foi preparado por método de deposição interfacial e sua caracterização foi realizada por determinação de pH, diâmetro médio e índice de polidispersão por espalhamento dinâmico de luz, potencial zeta por mobilidade eletroforética, eficiência de encapsulação por método de cromatografia líquida de alta eficiência e seu ensaio de citotoxicidade com linhagem de células queratinócitos (HaCaT) e células de cancer de mama (MCF-7). As formulações branca (C-NC) e contendo indometacina (Ind-OH-NC) mostraram leve pH ácido, diâmetros em torno de 200 nm e PDI0,2 com potencial zeta em torno de -20 mV e eficiência de encapsulação de 99% (1 mg.mL-1), cujo coeficiente de distribuição indicou efeito de permeação e retenção (efeito EPR). Ambas formulações não foram citotóxicas às células HaCaT, provando serem seguras às células normais e Ind-OH-NC teve uma permeação concentração e tempo-dependente e teve eficácia em reduzir a viabilidade celular da linhagem MCF-7.


Author(s):  
Sara Afzali ◽  
Abbas Doosti ◽  
Mansour Heidari ◽  
Nahid Babaei ◽  
Parvaneh Keshavarz

Introduction: Breast cancer is one of the most prevalent malignancies among women. Patients whose suffering from this condition, as a result of the use of conventional therapies often have a poor response to treatment and the relapse among them is frequent. In this study, the effects of staphylococcal enterotoxin type B on BAK، FAS، BAX، TNF-a، BCL-2 و Survivin genes expression in human breast adenocarcinoma cells (MCF-7) was examined. Staphylococcal enterotoxin B is a powerful member of the Staphylococcus aureus toxins family, which is known as an anticancer agent with potential for killing cancer cells. Methods: The experimental study was carried out at the Biotechnology Research Center of Islamic Azad University, Shahrekord Branch. By using Lipofectamine 2000 reagent, MCF-7  cells transfected with the pcDNA3.1(+)-seb (recombinant) and  pcDNA3.1(+) (non-recombinant)  plasmids and were selected by culturing in a selective medium of RPMI- 1640 containing 600 μg / mL antibiotic G418. Then, the expression of BAK, FAS, BAX, TNF-a, BCL-2, and Survivin genes in transfected cells were analyzed by real time PCR. Student's t-test, SPSS Inc., Chicago, IL; Version 16 and also Excel program for statistical analysis were used. Results: The results of this study indicated that staphylococcal enterotoxin type B (SEB) remarkably changes the expression of apoptotic related genes in MCF-7 cell line. It was observed a significant increase in the expression of BAK, FAS, BAX, and TNF-a genes, the expression of BCL-2 and Survivin genes significantly decreased compared to the control group (P=0/032). Conclusion: Staphylococcal enterotoxin type B has an inhibitory effect on the growth, proliferation and invasion of breast adenocarcinoma cells through altering the expression of the genes involved in the apoptosis process. Therefore, it seems that there is a good research field for the use of this toxin in the control and treatment of human breast adenocarcinoma.


Molbank ◽  
10.3390/m1083 ◽  
2019 ◽  
Vol 2019 (4) ◽  
pp. M1083
Author(s):  
Uwabagira ◽  
Sarojini

The compound 3-{[(2,3-Dichlorophenyl)amino]methyl}-5-(furan-2-ylmethylidene)-1,3-thiazolidine-2,4-dione has been designed, synthesized, and screened for its in vitro antibreast cancer activity, using human breast adenocarcinoma cell lines (MCF-7) and in vitro anti-inflammatory activity. By hemolysis assay, it showed that it has a nonhemolytic and nontoxic effect on human blood cell. The title compound 5, subjected to in vitro activities, showed that it is cytotoxic with an IC50 of 42.30 µM and a good anti-inflammatory agent. The docking results against cyclin dependent kinase 2 (CDK2) (PDB ID: 3QQK) gave insights on its inhibitory activity.


Sign in / Sign up

Export Citation Format

Share Document